Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression.

Immunobiology

Antohe I, Tanasa MP, Dăscălescu A, Dănăilă C, Titieanu A, Zlei M, Ivanov I, Sireteanu A, Cianga P.
PMID: 33352400
Immunobiology. 2021 Jan;226(1):152049. doi: 10.1016/j.imbio.2020.152049. Epub 2020 Dec 03.

Acute Myeloid Leukaemia (AML) is a neoplasia characterised by rapid proliferation and an increased rate of relapses. The AML blasts display features of antigen-presenting cells (APC), and thus can directly modulate the anti-tumour T cell responses. The bone marrow...

Cite
Antohe I, Tanasa MP, Dăscălescu A, et al. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression. Immunobiology. 2020;226(1):152049doi: 10.1016/j.imbio.2020.152049.
Antohe, I., Tanasa, M. P., Dăscălescu, A., Dănăilă, C., Titieanu, A., Zlei, M., Ivanov, I., Sireteanu, A., & Cianga, P. (2021). The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression. Immunobiology, 226(1), 152049. https://doi.org/10.1016/j.imbio.2020.152049
Antohe, Ion, et al. "The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression." Immunobiology vol. 226,1 (2021): 152049. doi: https://doi.org/10.1016/j.imbio.2020.152049
Antohe I, Tanasa MP, Dăscălescu A, Dănăilă C, Titieanu A, Zlei M, Ivanov I, Sireteanu A, Cianga P. The MHC-II antigen presentation machinery and B7 checkpoint ligands display distinctive patterns correlated with acute myeloid leukaemias blast cells HLA-DR expression. Immunobiology. 2021 Jan;226(1):152049. doi: 10.1016/j.imbio.2020.152049. Epub 2020 Dec 03. PMID: 33352400.
Copy Download .nbib Format: NLM
B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles.

Frontiers in oncology

Antohe I, Dǎscǎlescu A, Dǎnǎilǎ C, Titieanu A, Zlei M, Ivanov I, Sireteanu A, Pavel M, Cianga P.
PMID: 32231996
Front Oncol. 2020 Mar 13;10:264. doi: 10.3389/fonc.2020.00264. eCollection 2020.

Acute myeloid leukemia (AML) is generally considered a poorly immunogenic malignancy, displaying a "non-inflamed" leukemia microenvironment (LME), leading to T cell tolerance. However, the immune landscape of AML is much more heterogeneous. Since B7 expression is regarded as a...

Cite
Antohe I, Dǎscǎlescu A, Dǎnǎilǎ C, et al. B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles. Front Oncol. 2020;10:264doi: 10.3389/fonc.2020.00264.
Antohe, I., Dǎscǎlescu, A., Dǎnǎilǎ, C., Titieanu, A., Zlei, M., Ivanov, I., Sireteanu, A., Pavel, M., & Cianga, P. (2020). B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles. Frontiers in oncology, 10264. https://doi.org/10.3389/fonc.2020.00264
Antohe, Ion, et al. "B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles." Frontiers in oncology vol. 10 (2020): 264. doi: https://doi.org/10.3389/fonc.2020.00264
Antohe I, Dǎscǎlescu A, Dǎnǎilǎ C, Titieanu A, Zlei M, Ivanov I, Sireteanu A, Pavel M, Cianga P. B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint Receptor Expression, and European Leukemia Net Risk Profiles. Front Oncol. 2020 Mar 13;10:264. doi: 10.3389/fonc.2020.00264. eCollection 2020. PMID: 32231996; PMCID: PMC7082324.
Copy Download .nbib Format: NLM
Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma.

Journal of clinical medicine

Deak-Mihaly D, Iluta S, Pasca S, Jitaru C, Roman A, Andries A, Padurariu-Covit M, Petrushev B, Vasilache A, Bojan A, Zdrenghea M, Dascalescu A, Antohe I, Colita A, Colita A, Dima D, Tanase A, Tomuleasa C.
PMID: 34640501
J Clin Med. 2021 Sep 29;10(19). doi: 10.3390/jcm10194483.

INTRODUCTION: Primary central nervous system lymphoma is an uncommon form of extranodal non-Hodgkin's lymphoma, with increasing incidence, a relatively aggressive course and a poor 5-year survival. Because of its localization, the therapeutic compounds used in this disease must be...

Cite
Deak-Mihaly D, Iluta S, Pasca S, et al. Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma. J Clin Med. 2021;10(19)doi: 10.3390/jcm10194483.
Deak-Mihaly, D., Iluta, S., Pasca, S., Jitaru, C., Roman, A., Andries, A., Padurariu-Covit, M., Petrushev, B., Vasilache, A., Bojan, A., Zdrenghea, M., Dascalescu, A., Antohe, I., Colita, A., Colita, A., Dima, D., Tanase, A., & Tomuleasa, C. (2021). Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma. Journal of clinical medicine, 10(19), . https://doi.org/10.3390/jcm10194483
Deak-Mihaly, Dalma, et al. "Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma." Journal of clinical medicine vol. 10,19 (2021). doi: https://doi.org/10.3390/jcm10194483
Deak-Mihaly D, Iluta S, Pasca S, Jitaru C, Roman A, Andries A, Padurariu-Covit M, Petrushev B, Vasilache A, Bojan A, Zdrenghea M, Dascalescu A, Antohe I, Colita A, Colita A, Dima D, Tanase A, Tomuleasa C. Ibrutinib Monotherapy as Bridge-to-Transplant for Relapsed/Refractory Primary Oculo-Cerebral Lymphoma. J Clin Med. 2021 Sep 29;10(19). doi: 10.3390/jcm10194483. PMID: 34640501; PMCID: PMC8509719.
Copy Download .nbib Format: NLM
A very rare case of FLT3-D835 positive blastic plasmacytoid dendritic cell neoplasm.

Archive of clinical cases

Cianga VA, Dănăilă CD, Antohe I, Oană R, Mențel M, Ivanov I, Dragoș L, Dăscălescu AS.
PMID: 34754929
Arch Clin Cases. 2021 Oct 27;7(4):57-62. doi: 10.22551/2020.29.0704.10174. eCollection 2020.

Blastic plasmacytoid dendritic cell neoplasms (BPDCNs) are extremely rare and aggressive hematological malignancies that derive from precursors of plasmacytoid dendritic cells (pDC) and frequently involve skin lesions and bone marrow infiltration. They mostly affect the elderly population and the...

Cite
Cianga VA, Dănăilă CD, Antohe I, et al. A very rare case of FLT3-D835 positive blastic plasmacytoid dendritic cell neoplasm. Arch Clin Cases. 2021;7(4):57-62doi: 10.22551/2020.29.0704.10174.
Cianga, V. A., Dănăilă, C. D., Antohe, I., Oană, R., Mențel, M., Ivanov, I., Dragoș, L., & Dăscălescu, A. S. (2020). A very rare case of FLT3-D835 positive blastic plasmacytoid dendritic cell neoplasm. Archive of clinical cases, 7(4), 57-62. https://doi.org/10.22551/2020.29.0704.10174
Cianga, Vlad Andrei, et al. "A very rare case of FLT3-D835 positive blastic plasmacytoid dendritic cell neoplasm." Archive of clinical cases vol. 7,4 (2020): 57-62. doi: https://doi.org/10.22551/2020.29.0704.10174
Cianga VA, Dănăilă CD, Antohe I, Oană R, Mențel M, Ivanov I, Dragoș L, Dăscălescu AS. A very rare case of FLT3-D835 positive blastic plasmacytoid dendritic cell neoplasm. Arch Clin Cases. 2021 Oct 27;7(4):57-62. doi: 10.22551/2020.29.0704.10174. eCollection 2020. PMID: 34754929; PMCID: PMC8565708.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries